Revised forecast
Fiscal year ending March 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Business revenue increased due to income received from analytical services and other sources. In terms of earnings, research and development expenses were recorded as a result of the continued implementation of basic research and drug discovery research, as well as progress in clinical development in the three areas of small-molecule drugs, cancer peptide vaccines and antibody drugs. In addition, impairment accounting was applied to assets related to the cancer precision medicine business.
Impairment loss of ¥63 million (assets related to the cancer precision medicine business)
| Item | Details |
|---|---|
| Net Sales | 58 |
| Operating profit | -12 |
| Ordinary income | -30 |
| Profit attributable to owners of the parent | -95 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Business revenue ¥750 million, operating loss ¥797 million, ordinary loss ¥815 million, net loss attributable to owners of the parent ¥815 million, and loss per share ¥3.12 |
| Reason for the revision | Business revenue increased due to income received from analytical services and other sources. In terms of earnings, research and development expenses were recorded as a result of the continued implementation of basic research and drug discovery research, as well as progress in clinical development in the three areas of small-molecule drugs, cancer peptide vaccines and antibody drugs. In addition, impairment accounting was applied to assets related to the cancer precision medicine business. |
| Details and amount of extraordinary loss | Impairment loss of ¥63 million (assets related to the cancer precision medicine business) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue increased due to income received from analytical services and other sources. However, operating and ordinary losses widened because research and development expenses were recorded in connection with the continuation of basic research and drug discovery research on drug candidate compounds, as well as progress in clinical development in the three areas of small-molecule drugs, cancer peptide vaccines and antibody drugs. In addition, an impairment loss of ¥63 million was recorded on assets related to the cancer precision medicine business, resulting in a wider net loss for the fiscal year.